Sign In
Buy EVOK
$11.00
+0 (+0%)
At Close: Mar 16, 2026
CLEVELAND--(BUSINESS WIRE)--Partnership creates national RIA with 600 employees and $65 billion in AUM.
William Hill owner Evoke threatens betting shop closures if taxes go up
04:16am, Monday, 13'th Oct 2025
William Hill owner Evoke PLC (LSE:EVOK) has joined Ladbrokes owner Entain PLC (LSE:ENT) in threatening to close hundreds of betting shops if November's Budget brings new taxes on the industry.
Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year
09:08am, Friday, 03'rd Oct 2025
LOS ANGELES--(BUSINESS WIRE)--Ranking recognizes Evoke's achievement in advancing client experience, and its leadership as a trusted advisor in the RIA industry.
MAI Capital Management Announces Strategic Partnership with Evoke Advisors
09:30am, Wednesday, 27'th Aug 2025
CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
07:00am, Tuesday, 26'th Aug 2025
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
07:00am, Thursday, 21'st Aug 2025
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
06:30am, Wednesday, 06'th Aug 2025
Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection Extends market exclusivity for GIMOTI® to November 2038, nearly two additional ye
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
08:16am, Wednesday, 09'th Jul 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
04:05pm, Tuesday, 13'th May 2025
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIR
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasi
evoke makes a steady exit from the Q1 starting gate
02:42am, Friday, 25'th Apr 2025
Evoke PLC (LSE:EVOK) has kicked off 2025 with a steady start, reporting first-quarter revenue of £437.00 million—up 1% on last year and pretty much bang on with what it had guided. So far this yea
William Hill owner Evoke falls at the first-quarter update
05:01am, Wednesday, 26'th Mar 2025
Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calen
Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript
08:36pm, Thursday, 13'th Mar 2025
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng – DKB Partners Matt D'Onofrio – Chief Executive Officer Chri
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:02pm, Thursday, 13'th Mar 2025
Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025
08:30am, Thursday, 06'th Mar 2025
SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasi
